DOCSLIB.ORG

Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer Tohoku J. Exp. Med., 2018, 244PGF, is291-296 a Prognostic Biomarker in Advanced-Stage Serous Ovarian Cancer 291 Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer Qin Meng,1 Pengjing Duan,2 Lin Li3 and Yongmei Miao3 1Department of Gynecology and Obstetrics, Shandong Medical College Linyi, Shandong, China 2Department of Gynecology and Obstetrics, Affiliated Hospital of Shandong Medical College Linyi, Shandong, China 3Department of Gynecology and Obstetrics, Linyi People’s Hospital, Linyi, Shandong, China Ovarian cancer is the fourth leading cause of cancer death in women and the most fatal gynecologic malignancy. Placenta growth factor (PGF), a member of the vascular endothelial growth factor, plays an important role in angiogenesis. The overexpression of PGF was observed in several types of cancers, but the clinical significance of PGF in epithelial ovarian cancer (EOC) is still unknown. To explore the prognostic value of PGF among patients with serous EOC, we analyzed the expression of PGF in 89 EOC specimens by immunohistochemistry. The scoring system of immunohistochemistry was based on the staining intensity and the percentage of PGF-positive cells in each EOC tissue. According to the immunohistochemical score, 34 patients with score ≥ 6 were defined as high PGF expression, and other 55 patients were the group with low PGF expression. The prognostic significance of PGF expression was analyzed. EOC patients with higher IHC scores of PGF expression are significantly associated with positive lymphatic invasion and poorer response to chemotherapy. Patients with higher IHC scores of PGF expression had poorer response to chemotherapy and lower overall survival rate. Additionally, the positive lymph node metastasis, advanced TNM stage, and poorer response to chemotherapy were all remarkably correlated to poorer prognosis. In conclusion, patients with higher PGF in EOC tissues were more predisposed to positive lymphatic invasion, poorer response to chemotherapy and unfavorable prognosis of patients with serous EOC. We propose that PGF expression may be predictive of chemoresistance and poor prognosis of serous EOC. Keywords: biomarker; chemoresistance; placenta growth factor; prognosis; serous ovarian cancer Tohoku J. Exp. Med., 2018 April, 244 (4), 291-296. © 2018 Tohoku University Medical Press of patients with chemoresistance are only 25%-35% Introduction (Colombo et al. 2014). The current standard treatment for Ovarian cancer is the fourth leading cause of cancer epithelial ovarian cancer (EOC) is the aggressive surgical death in women and the most fatal gynecologic malignancy cytoreduction followed by adjuvant chemotherapy. New with about 200,000 newly diagnosed patients and 15,000 treatment approaches and modified chemotherapies rely on deaths (Jeruss and Woodruff 2009; Zaid et al. 2013). As a the exploration of new biomarkers and drug targets. Thus, heterogeneous group of neoplasms, ovarian cancers mainly the prognostic and predictive biomarkers for EOC are still consist of malignant epithelial tumors (Cho and Shih Ie in urgent need. 2009). The histological subtypes generally include serous, Placenta growth factor (PGF), a member of the vascu- endometrioid, clear cell and mucinous adenocarcinomas lar endothelial growth factor (VEGF) sub-family, plays an (Basu et al. 2014). Unfortunately, partially because of no important role in angiogenesis and endothelial cells growth specific symptoms at the early stage, approximately 70% of (Rolny et al. 2011). PGF could be secreted out and trigger patients are present with a diagnosis of ovarian carcinoma downstream signaling pathway mainly by binding to in an advanced stage (Barnes et al. 2002). In the past VEGFR-1 or neuropilin (Rolny et al. 2011). PGF is highly decades, with the progress of modern surgeries and adju- expressed in placenta throughout all stages of gestation. As vant chemotherapies, the overall prognosis of patients with a key member of angiogenesis, PGF is expressed in endo- ovarian cancers have improved remarkably, but most thelial cells of many organs including ovary (De Falco patients would experience the relapse and the overall sur- 2012). The aberrant expression of PGF is associated with vival rate remains unsatisfactory. The 5-year survival rates many kinds of human diseases. For example, serum PGF is Received January 15, 2018; revised and accepted March 12, 2018. Published online April 10, 2018; doi: 10.1620/tjem.244.291. Correspondence: Yongmei Miao, M.D., Department of Gynecology and Obstetrics, Linyi People’s Hospital, 27# Jiefang Road, Linyi, Shandong 264000, China. e-mail: [email protected] 291 292 Q. Meng et al. a potential biomarker for preeclampsia during pregnancy. pathologists who were blind to the clinical data. The score system of In both early and late onset preeclampsia, maternal serum IHC was dependent on the staining intensity and positive cells per- levels of PGF are lower in women presenting with pre- centage according to previous studies (Liu et al. 2017a; Xu et al. eclampsia (Khalil et al. 2008). The elevation of PGF 2017). The score of staining intensity was defined as follows: 0, neg- expression was reported in many types of cancers, includ- ative; 1, weak; 2, moderate; and 3, strong. The score of positive cells ing gastric cancer, colorectal cancer, hepatocellular carci- percentage was defined as follows: 1, < 25% of positive cells; 2, 25%-50% of positive cells; 3, 50%-75% of positive cells; and 4, 75%- noma, breast cancer and lung cancer (Dewerchin and 100% of positive cells. Thus, the final IHC score was calculated as Carmeliet 2014; Song et al. 2016). In ovarian cancer cells, the product of the score of staining intensity multiplied by the score PGF has been demonstrated to promote cell invasion via of positive cells percentage, from 0 to 12. The optimal cut-off of PGF activating zinc finger E-box-binding homeobox 2 (ZEB2) expression was identified by the point with the highest sum of sensi- and promote metastases via suppressing miR-543 and up- tivity and specificity in ROC curve, which was 5.0 in our test. The regulating MMP7 (Song et al. 2015, 2016). However, all total cohort was divided into the group with high expression of PGF the previous studies were limited in experiments in vitro, (score ≥ 6) and the group with low expression of PGF (score ≤ 4) and the clinical significance of PGF in EOC is still with the optimal cut-off. unknown. In this study, we enrolled 89 patients with serous EOC Statistical analysis and investigated the expression of PGF with immuhohisto- All the significant differences were analyzed with SPSS 22.0 chemistry (IHC). By univariate and multivariate analysis, software (SPSS, Inc., Chicago, IL, USA). The correlation between we evaluated the prognostic significance of PGF among the expression of PGF and the clinicopathological parameters was patients with serous EOC. analyzed with Fisher test. The survival curves were estimated with the Kaplan-Meier method and the statistical significance of different Materials and Methods groups was accessed by the log-rank test. The Cox’s regression pro- portional hazards model is applied to identify the independent prog- Patients and follow-ups nostic factors and the hazard ratio (HR) with 95% confidence interval This study was approved and supervised by the Ethics (95% CI) was used to evaluate the prognostic value. P-value < 0.05 Committee of the Affiliated Hospital of Shandong Medical College was considered statistically significant. and the Ethics Committee of Linyi People’s Hospital. There are total 353 patients who underwent surgery of EOC in the Affiliated Hospital of Shandong Medical College and the Linyi People’s Hospital from Results 2009 to 2013. Total of 89 patients were selected following the inclu- PGF expression is mainly in the cytoplasm of EOC tissues sion criteria: (1) the pathological type was serous ovarian cancer and The expression of PGF in serous ovarian cancer was the first operation was in advanced-stage (stage IIIB to IV), (2) there detected with IHC. In EOC tissues, PGF was mainly were available follow-ups and tissues for IHC, (3) there were no che- observed in the intracellular cytoplasm. According to the motherapies or radiotherapies before surgery, (4) patients got sys- cut-off, the cohort of our study was divided into the groups temic platinum-based chemotherapy after the operation, and (5) there of low PGF expression and high PGF expression (Fig. 1A, were no severe complications and other tumors occurred post-opera- B), which accounted for 61.8% (55/89) and 38.2% (34/89), tionally. The age of patients ranged from 41 to 73 years old, with the respectively. average age as 54.3 years old. The written informed consents were obtained from patients or their families. Optimal Debulking surgery was defined as a residual tumor no more than 1 cm in diameter PGF is associated with lymph node metastasis, TNM stage according to previous study (Zaid et al. 2013). The TNM stage of and response to chemotherapy patients was according to the AJCC/UICC staging system. The correlations between PGF expression and the clin- icopathological factors were analyzed by the Fisher test Immunohistochemistry (Table 1). In our study, high expression of PGF was signifi- The paraffin-embedded specimens of serous EOC were sliced cantly associated with positive lymph node metastasis (P = into 4-μm sections for IHC according to previous studies (Xu et al. 0.004), indicating that high PGF may promote
Load more

Recommended publications
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • Pathophysiological Roles of FGF Signaling in the Heart
    MINI REVIEW ARTICLE published: 06 September 2013 doi: 10.3389/fphys.2013.00247 Pathophysiological roles of FGF signaling in the heart Nobuyuki Itoh* and Hiroya Ohta Department of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Sciences, Kyoto, Japan Edited by: Cardiac remodeling progresses to heart failure, which represents a major cause of Marcel van der Heyden, University morbidity and mortality. Cardiomyokines, cardiac secreted proteins, may play roles Medical Center, Netherlands in cardiac remodeling. Fibroblast growth factors (FGFs) are secreted proteins with Reviewed by: diverse functions, mainly in development and metabolism. However, some FGFs play Marcel van der Heyden, University Medical Center, Netherlands pathophysiological roles in cardiac remodeling as cardiomyokines. FGF2 promotes cardiac Christian Faul, University of Miami hypertrophy and fibrosis by activating MAPK signaling through the activation of FGF Miller School of Medicine, USA receptor (FGFR) 1c. In contrast, FGF16 may prevent these by competing with FGF2 for the *Correspondence: binding site of FGFR1c. FGF21 prevents cardiac hypertrophy by activating MAPK signaling Nobuyuki Itoh, Department of through the activation of FGFR1c with β-Klotho as a co-receptor. In contrast, FGF23 Genetic Biochemistry, Kyoto α University Graduate School of induces cardiac hypertrophy by activating calcineurin/NFAT signaling without Klotho. Pharmaceutical Sciences, These FGFs play crucial roles in cardiac remodeling via distinct action mechanisms. These Yoshida-Shimoadachi, Sakyo, findings provide new insights into the pathophysiological roles of FGFs in the heart and Kyoto 606-8501, Japan may provide potential therapeutic strategies for heart failure. e-mail: itohnobu@ pharm.kyoto-u.ac.jp Keywords: FGF, heart, hypertrophy, fibrosis, heart failure, cardiomyokine INTRODUCTION mice and humans, respectively.
    [Show full text]
  • Instability Restricts Signaling of Multiple Fibroblast Growth Factors
    Cell. Mol. Life Sci. DOI 10.1007/s00018-015-1856-8 Cellular and Molecular Life Sciences RESEARCH ARTICLE Instability restricts signaling of multiple fibroblast growth factors Marcela Buchtova • Radka Chaloupkova • Malgorzata Zakrzewska • Iva Vesela • Petra Cela • Jana Barathova • Iva Gudernova • Renata Zajickova • Lukas Trantirek • Jorge Martin • Michal Kostas • Jacek Otlewski • Jiri Damborsky • Alois Kozubik • Antoni Wiedlocha • Pavel Krejci Received: 18 June 2014 / Revised: 7 February 2015 / Accepted: 9 February 2015 Ó Springer Basel 2015 Abstract Fibroblast growth factors (FGFs) deliver ex- failure to activate FGF receptor signal transduction over tracellular signals that govern many developmental and long periods of time, and influence specific cell behavior regenerative processes, but the mechanisms regulating FGF in vitro and in vivo. Stabilization via exogenous heparin signaling remain incompletely understood. Here, we ex- binding, introduction of stabilizing mutations or lowering plored the relationship between intrinsic stability of FGF the cell cultivation temperature rescues signaling of un- proteins and their biological activity for all 18 members of stable FGFs. Thus, the intrinsic ligand instability is an the FGF family. We report that FGF1, FGF3, FGF4, FGF6, important elementary level of regulation in the FGF sig- FGF8, FGF9, FGF10, FGF16, FGF17, FGF18, FGF20, and naling system. FGF22 exist as unstable proteins, which are rapidly de- graded in cell cultivation media. Biological activity of Keywords Fibroblast growth factor Á FGF Á Unstable Á FGF1, FGF3, FGF4, FGF6, FGF8, FGF10, FGF16, FGF17, Proteoglycan Á Regulation and FGF20 is limited by their instability, manifesting as Electronic supplementary material The online version of this article (doi:10.1007/s00018-015-1856-8) contains supplementary material, which is available to authorized users.
    [Show full text]
  • FGF Signaling Network in the Gastrointestinal Tract (Review)
    163-168 1/6/06 16:12 Page 163 INTERNATIONAL JOURNAL OF ONCOLOGY 29: 163-168, 2006 163 FGF signaling network in the gastrointestinal tract (Review) MASUKO KATOH1 and MASARU KATOH2 1M&M Medical BioInformatics, Hongo 113-0033; 2Genetics and Cell Biology Section, National Cancer Center Research Institute, Tokyo 104-0045, Japan Received March 29, 2006; Accepted May 2, 2006 Abstract. Fibroblast growth factor (FGF) signals are trans- Contents duced through FGF receptors (FGFRs) and FRS2/FRS3- SHP2 (PTPN11)-GRB2 docking protein complex to SOS- 1. Introduction RAS-RAF-MAPKK-MAPK signaling cascade and GAB1/ 2. FGF family GAB2-PI3K-PDK-AKT/aPKC signaling cascade. The RAS~ 3. Regulation of FGF signaling by WNT MAPK signaling cascade is implicated in cell growth and 4. FGF signaling network in the stomach differentiation, the PI3K~AKT signaling cascade in cell 5. FGF signaling network in the colon survival and cell fate determination, and the PI3K~aPKC 6. Clinical application of FGF signaling cascade in cell polarity control. FGF18, FGF20 and 7. Clinical application of FGF signaling inhibitors SPRY4 are potent targets of the canonical WNT signaling 8. Perspectives pathway in the gastrointestinal tract. SPRY4 is the FGF signaling inhibitor functioning as negative feedback apparatus for the WNT/FGF-dependent epithelial proliferation. 1. Introduction Recombinant FGF7 and FGF20 proteins are applicable for treatment of chemotherapy/radiation-induced mucosal injury, Fibroblast growth factor (FGF) family proteins play key roles while recombinant FGF2 protein and FGF4 expression vector in growth and survival of stem cells during embryogenesis, are applicable for therapeutic angiogenesis. Helicobacter tissues regeneration, and carcinogenesis (1-4).
    [Show full text]
  • Supplementary Information
    Supplementary information Supplemental Figure 1. No tissue contamination is confirmed by immunostaining of anti-MHC antibodies in the human-mouse heterogeneous recombination. A: The mesenchymally exclusive expression of human MHC in recombinant of mouse dental epithelium and human dental mesenchyme after subrenal culture for 4 weeks. B: The mesenchymally exclusive expression of mouse MHC in the recombinant of human dental epithelium and mouse dental mesenchyme after subrenal culture for 7 days. C: The epithelially exclusive expression of human MHC in the recombinant of human dental epithelium and mouse dental mesenchyme after subrenal culture for 7 days. hdm, human bell-stage dental mesenchyme; mam, mouse ameloblasts; mdm, E13.5 mouse dental mesenchyme; hde, human bell-stage dental epithelium. Scale bar = 50 μm. Supplemental Figure 2. Expression pattern of FGF1, FGF2, FGF15/19, and FGF18 in human tooth germs at the cap and bell stages. In situ hybridization shows the expression of FGF1 (A, B), FGF2 (C, D), FGF15/19 (E, F), and FGF18 (G, H) in human molar germs at the cap (A, C, E, G) and bell (B, D, F, H) stages. de, dental epithelium; dm, dental mesenchyme; ek, enamel knot; sr, stellate reticulum; iee, inner enamel epithelium. Scale bar = 50 μm. Supplemental Figure 3. Fgf8 is ectopically expressed in E13.5 molar germs of Wnt1-Cre;R26RFgf8 mice. Immunostaining of FGF8 in E13.5 wild-type (A) and mutant (B) molar germs. de, dental epithelium; dm, dental mesenchyme. Scale bar: 50 μm. Supplemental Table 1. Comparison of the expression pattern of FGF ligands between human and mouse tooth germ at the cap and bell stages.
    [Show full text]
  • DNA Hypermethylation of Fgf16 and Tbx22 Associated with Cleft Palate During Palatal Fusion
    Original Article http://dx.doi.org/10.1590/1678-7757-2018-0649 DNA hypermethylation of Fgf16 and Tbx22 associated with cleft palate during palatal fusion Abstract Xuan SHU1 Objective: Cleft palate (CP) is a congenital birth defect caused by the failure of palatal fusion. Little is known about the potential role of DNA methylation Zejun DONG1 in the pathogenesis of CP. This study aimed to explore the potential role of Liuhanghang CHENG1 DNA methylation in the mechanism of CP. Methodology: We established an Shenyou SHU1 all-trans retinoic acid (ATRA)-induced CP model in C57BL/6J mice and used methylation-dependent restriction enzymes (MethylRAD, FspEI) combined with high-throughput sequencing (HiSeq X Ten) to compare genome-wide DNA methylation profiles of embryonic mouse palatal tissues, between embryos from ATRA-treated vs. untreated mice, at embryonic gestation day 14.5 (E14.5) (n=3 per group). To confirm differentially methylated levels of susceptible genes, real-time quantitative PCR (qPCR) was used to correlate expression of differentially methylated genes related to CP. Results: We identified 196 differentially methylated genes, including 17,298 differentially methylated CCGG sites between ATRA-treated vs. untreated embryonic mouse palatal tissues (P<0.05, log2FC>1). The CP-related genes Fgf16 (P=0.008, log2FC=1.13) and Tbx22 (P=0.011, log2FC=1.64,) were hypermethylated. Analysis of Fgf16 and Tbx22, using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG), identified 3 GO terms and 1 KEGG pathway functionally related to palatal fusion. The qPCR showed that changes in expression level negatively correlated with methylation levels.
    [Show full text]
  • Expression of Fgfs During Early Mouse Tongue Development
    Gene Expression Patterns 20 (2016) 81e87 Contents lists available at ScienceDirect Gene Expression Patterns journal homepage: http://www.elsevier.com/locate/gep Expression of FGFs during early mouse tongue development * Wen Du a, b, Jan Prochazka b, c, Michaela Prochazkova b, c, Ophir D. Klein b, d, a State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, China b Department of Orofacial Sciences and Program in Craniofacial Biology, University of California San Francisco, San Francisco, CA 94143, USA c Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic d Department of Pediatrics and Institute for Human Genetics, University of California San Francisco, San Francisco, CA 94143, USA article info abstract Article history: The fibroblast growth factors (FGFs) constitute one of the largest growth factor families, and several Received 29 September 2015 ligands and receptors in this family are known to play critical roles during tongue development. In order Received in revised form to provide a comprehensive foundation for research into the role of FGFs during the process of tongue 13 December 2015 formation, we measured the transcript levels by quantitative PCR and mapped the expression patterns by Accepted 29 December 2015 in situ hybridization of all 22 Fgfs during mouse tongue development between embryonic days (E) 11.5 Available online 31 December 2015 and E14.5. During this period, Fgf5, Fgf6, Fgf7, Fgf9, Fgf10, Fgf13, Fgf15, Fgf16 and Fgf18 could all be detected with various intensities in the mesenchyme, whereas Fgf1 and Fgf2 were expressed in both the Keywords: Tongue epithelium and the mesenchyme.
    [Show full text]
  • FGF/FGFR Signaling in Health and Disease
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN FGF/FGFR signaling in health and disease Yangli Xie1, Nan Su1, Jing Yang1, Qiaoyan Tan1, Shuo Huang 1, Min Jin1, Zhenhong Ni1, Bin Zhang1, Dali Zhang1, Fengtao Luo1, Hangang Chen1, Xianding Sun1, Jian Q. Feng2, Huabing Qi1 and Lin Chen 1 Growing evidences suggest that the fibroblast growth factor/FGF receptor (FGF/FGFR) signaling has crucial roles in a multitude of processes during embryonic development and adult homeostasis by regulating cellular lineage commitment, differentiation, proliferation, and apoptosis of various types of cells. In this review, we provide a comprehensive overview of the current understanding of FGF signaling and its roles in organ development, injury repair, and the pathophysiology of spectrum of diseases, which is a consequence of FGF signaling dysregulation, including cancers and chronic kidney disease (CKD). In this context, the agonists and antagonists for FGF-FGFRs might have therapeutic benefits in multiple systems. Signal Transduction and Targeted Therapy (2020) 5:181; https://doi.org/10.1038/s41392-020-00222-7 INTRODUCTION OF THE FGF/FGFR SIGNALING The binding of FGFs to the inactive monomeric FGFRs will Fibroblast growth factors (FGFs) are broad-spectrum mitogens and trigger the conformational changes of FGFRs, resulting in 1234567890();,: regulate a wide range of cellular functions, including migration, dimerization and activation of the cytosolic tyrosine kinases by proliferation, differentiation, and survival. It is well documented phosphorylating the tyrosine residues within the cytosolic tail of that FGF signaling plays essential roles in development, metabo- FGFRs.4 Then, the phosphorylated tyrosine residues serve as the lism, and tissue homeostasis.
    [Show full text]
  • Halotag Is an Effective Expression and Solubilisation Fusion Partner for a Range of Fibroblast Growth Factors
    HaloTag is an eVective expression and solubilisation fusion partner for a range of fibroblast growth factors Changye Sun1,3 , Yong Li1,3 , Sarah E. Taylor1, Xianqing Mao2, Mark C. Wilkinson1 and David G. Fernig1 1 Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, UK 2 Department of Oncology, Laboratory of Cellular and Molecular Oncology, Luxembourg Institute of Health, Luxembourg 3 These authors contributed equally to this work. ABSTRACT The production of recombinant proteins such as the fibroblast growth factors (FGFs) is the key to establishing their function in cell communication. The production of recombinant FGFs in E. coli is limited, however, due to expression and solubility problems. HaloTag has been used as a fusion protein to introduce a genetically- encoded means for chemical conjugation of probes. We have expressed 11 FGF proteins with an N-terminal HaloTag, followed by a tobacco etch virus (TEV) protease cleavage site to allow release of the FGF protein. These were purified by heparin-aYnity chromatography, and in some instances by further ion-exchange chromatography. It was found that HaloTag did not adversely aVect the expression of FGF1 and FGF10, both of which expressed well as soluble proteins. The N-terminal HaloTag fusion was found to enhance the expression and yield of FGF2, FGF3 and FGF7. Moreover, whereas FGF6, FGF8, FGF16, FGF17, FGF20 and FGF22 were only expressed as insoluble proteins, their N-terminal HaloTag fusion counterparts (Halo-FGFs) were soluble, and could be successfully purified. However, cleavage of Halo-FGF6, -FGF8 and -FGF22 with TEV resulted in aggregation of the FGF protein.
    [Show full text]
  • Dissertation LFS Corrected 08-22-16
    EXPRESSION AND ROLE OF FIBROBLAST GROWTH FACTOR 9 (FGF9) IN BOVINE FOLLICULOGENESIS By LUÍS FERNANDO SCHÜTZ Doctor of Veterinary Medicine Federal University of Rio Grande do Sul Porto Alegre, Brazil 2007 Master of Science in Animal Science Santa Catarina State University Lages, Brazil Submitted to the Faculty of the Graduate College of the Oklahoma State University in partial fulfillment of the requirements for the Degree of DOCTOR OF PHILOSOPHY July, 2016 EXPRESSION AND ROLE OF FIBROBLAST GROWTH FACTOR 9 (FGF9) IN BOVINE FOLLICULOGENESIS Dissertation Approved: Dr. Leon J. Spicer Dissertation Adviser Dr. Robert Wettemann Dr. Glenn Zhang Dr. Peter Hoyt ii ACKNOWLEDGEMENTS To my beloved wife, for her love, support, encouragement, and understanding. She made all the steps of the arduous pathway to achieve this degree much easier. With her by my side, I feel much stronger. To my family in Brazil: my beloved parents, my brother, Lipe, and my sister, Ane, for their love, faith, and support. And to my beautiful niece, Sofia, my sister-in-law, Manuela, and my brother-in-law, Joni. To my advisor and mentor, Dr. Leon Spicer, for accepting me as a student, for giving me priceless lessons and advice whenever I needed, for stimulating me to develop a critical thinking, and for teaching me how to perform sound science in the field of ovarian folliculogenesis. And to his family, Michael, Melissa, Anna, and Richie, for their friendship and support. To the Franceschi family: my mother-in-law, Pierina, and my father-in-law, Adi, for their support and encouragement; to my brother-in-law, Junior, his wife, Janine, and his great boys, Bernardo and Bruno; and to my sister-in-law, Sheila, and her fiancé, Fábio.
    [Show full text]
  • University of Cincinnati
    UNIVERSITY OF CINCINNATI Date: ___ Feb 20th, 2008 I, Siyun Liao, hereby submit this work as part of the requirements for the degree of: ________________Doctor of Philosophy in: Molecular, Cellular and Biochemical Pharmacology It is entitled: ____The Role of Fibroblast Grown Factor-2 Isoforms in ___Ischemia-Reperfusion Injury and Cardioprotection This work and its defense approved by: Chair: Jo El J. Schultz, Ph.D. Thomas Doetschman, Ph.D. W. Keith Jones, Ph.D. Evangelia G. Kranias, Ph.D. Mark Olah, Ph.D. Hong-Sheng Wang, Ph.D. THE ROLE OF FIBROBLAST GROWTH FACTOR-2 ISOFORMS IN ISCHEMIA- REPERFUSION INJURY AND CARDIOPROTECTION A dissertation submitted to the Division of Graduate Studies of the University of Cincinnati In partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY In the Department of Pharmacology and Cell Biophysics 2007 by Siyun Liao B.S. China Pharmaceutical University, 2000 Committee Chair: Dr. Jo El J. Schultz ii Abstract Cardiovascular disease (CVD) remains the leading cause of death in the United States and in the developing world, with ischemic heart disease the second most common form of CVD. Experimental and clinical studies have demonstrated that a number of interventions, including brief periods of ischemia or hypoxia and certain endogenous molecules such as growth factors, opioids, adenosine or pharmacological agents are capable of protecting the heart against post- ischemic cardiac dysfunction, arrhythmias and myocardial infarction. One of these growth factors, fibroblast growth factor-2 (FGF2), has been implicated to be a cardioprotective molecule. FGF2 consists of multiple protein isoforms (low molecular weight, LMW, and high molecular weight, HMW) produced by alternative translation from the Fgf2 gene and these protein isoforms are localized to different cellular compartments indicating unique biological activity.
    [Show full text]
  • Termination of Receptor Tyrosine Kinase Signal
    International Journal of Molecular Sciences Review All Good Things Must End: Termination of Receptor Tyrosine Kinase Signal Azzurra Margiotta 1,2 1 Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic; [email protected] 2 International Clinical Research Center, St. Anne’s University Hospital, 65691 Brno, Czech Republic Abstract: Receptor tyrosine kinases (RTKs) are membrane receptors that regulate many fundamental cellular processes. A tight regulation of RTK signaling is fundamental for development and survival, and an altered signaling by RTKs can cause cancer. RTKs are localized at the plasma membrane (PM) and the major regulatory mechanism of signaling of RTKs is their endocytosis and degradation. In fact, RTKs at the cell surface bind ligands with their extracellular domain, become active, and are rapidly internalized where the temporal extent of signaling, attenuation, and downregulation are modulated. However, other mechanisms of signal attenuation and termination are known. Indeed, inhibition of RTKs’ activity may occur through the modulation of the phosphorylation state of RTKs and the interaction with specific proteins, whereas antagonist ligands can inhibit the biological responses mediated by the receptor. Another mechanism concerns the expression of endogenous inactive receptor variants that are deficient in RTK activity and take part to inactive heterodimers or hetero-oligomers. The downregulation of RTK signals is fundamental for several cellular functions and the homeostasis of the cell. Here, we will review the mechanisms of signal attenuation and termination of RTKs, focusing on FGFRs. Keywords: RTKs; FGFRs; termination of signaling; degradation; ubiquitination; PTPs; kinases Citation: Margiotta, A. All Good Things Must End: Termination of Receptor Tyrosine Kinase Signal.
    [Show full text]